BACKGROUND: Evidence suggests that rates of gastroesophageal reflux disease are increasing in the Asia-Pacific region, where patients tend to have predominantly non-erosive reflux disease as opposed to erosive (reflux) esophagitis. At present, data for the responsiveness of non-erosive reflux disease to proton pump inhibition are scant. We aimed to study esomeprazole for the treatment of non-erosive reflux disease in Chinese patients. METHODS:Patients with a clinical diagnosis of gastroesophageal reflux, and a locally validated reflux index, the Chinese GerdQ, of equal to or greater than 12 were recruited and randomized to receive esomeprazole 20 mg daily or placebo for 8 weeks. Reflux index scores, quality of life (SF-36), and the hospital anxiety and depression (HAD) scale and symptom relief were evaluated before, during, and after treatment. RESULTS: A total of 175 patients were randomized. Patients in the esomeprazolegroup (n = 85) demonstrated statistically significant reductions in their GerdQ index, from 19.45 to 15.37 and to 14.32 (p = 0.013, p = 0.005) at weeks 4 and 8, respectively. Compared to placebo at week 8, 57.1% of patients on esomeprazole found that their symptoms had resolved or were acceptable compared with 37.2% in the placebogroup (p = 0.001). There were no statistically significant differences in overall quality-of-life measures or the HAD scale related to treatment. CONCLUSIONS: This study suggests that esomeprazole is efficacious in treating Chinese patients with non-erosive reflux disease.
RCT Entities:
BACKGROUND: Evidence suggests that rates of gastroesophageal reflux disease are increasing in the Asia-Pacific region, where patients tend to have predominantly non-erosive reflux disease as opposed to erosive (reflux) esophagitis. At present, data for the responsiveness of non-erosive reflux disease to proton pump inhibition are scant. We aimed to study esomeprazole for the treatment of non-erosive reflux disease in Chinese patients. METHODS:Patients with a clinical diagnosis of gastroesophageal reflux, and a locally validated reflux index, the Chinese GerdQ, of equal to or greater than 12 were recruited and randomized to receive esomeprazole 20 mg daily or placebo for 8 weeks. Reflux index scores, quality of life (SF-36), and the hospital anxiety and depression (HAD) scale and symptom relief were evaluated before, during, and after treatment. RESULTS: A total of 175 patients were randomized. Patients in the esomeprazole group (n = 85) demonstrated statistically significant reductions in their GerdQ index, from 19.45 to 15.37 and to 14.32 (p = 0.013, p = 0.005) at weeks 4 and 8, respectively. Compared to placebo at week 8, 57.1% of patients on esomeprazole found that their symptoms had resolved or were acceptable compared with 37.2% in the placebo group (p = 0.001). There were no statistically significant differences in overall quality-of-life measures or the HAD scale related to treatment. CONCLUSIONS: This study suggests that esomeprazole is efficacious in treating Chinese patients with non-erosive reflux disease.
Authors: Y Chan; J Y L Ching; C M Y Cheung; K K F Tsoi; S Polder-Verkiel; S H Y Pang; W L Quan; K M Kee; F K L Chan; J J Y Sung; J C Y Wu Journal: Aliment Pharmacol Ther Date: 2009-10-31 Impact factor: 8.171
Authors: W M Wong; K F Lam; K C Lai; W M Hui; W H C Hu; C L K Lam; N Y H Wong; H H X Xia; J Q Huang; A O O Chan; S K Lam; B C Y Wong Journal: Aliment Pharmacol Ther Date: 2003-06-01 Impact factor: 8.171
Authors: R Fass; W D Chey; S F Zakko; N Andhivarothai; R N Palmer; M C Perez; S N Atkinson Journal: Aliment Pharmacol Ther Date: 2009-04-08 Impact factor: 8.171
Authors: Ying L Xiao; Jin K Lin; Ting K Cheung; Nina Y H Wong; Ivan F N Hung; Benjamin C Y Wong; Sui Peng; An J Wang; Min H Chen Journal: J Gastroenterol Hepatol Date: 2009-06 Impact factor: 4.029
Authors: Irvin M Modlin; Richard H Hunt; Peter Malfertheiner; Paul Moayyedi; Eamon M Quigley; Guido N J Tytgat; Jan Tack; Gerald Holtmann; Steven F Moss Journal: Digestion Date: 2008-10-02 Impact factor: 3.216
Authors: Taline A Boghossian; Farah Joy Rashid; Wade Thompson; Vivian Welch; Paul Moayyedi; Carlos Rojas-Fernandez; Kevin Pottie; Barbara Farrell Journal: Cochrane Database Syst Rev Date: 2017-03-16